Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Novavax (NVAX) Tops Q2 EPS by 1c
August 10, 2015 4:16 PM EDTNovavax (NASDAQ: NVAX) reported Q2 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $14 million versus the consensus estimate of $9.9 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
... MoreNovavax (NVAX) Announces RSV F Vaccine Phase 2 Met All Objectives in Older Adults
August 10, 2015 4:11 PM EDTNovavax (NASDAQ: NVAX) announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older). The RSV F Vaccine was well-tolerated and fulfilled the Company's expectations of the primary, secondary and exploratory objectives of the trial.
"It's increasingly appreciated that RSV causes an enormous amount of illness on an annual basis, particularly in the older population. An RSV infection can predispose older adults to developing secondary pneumonia and admission to the hospital," said Dr. William Schaffner, Professor of... More
